Objective—To compare values of lower urogenital tract urodynamic and morphometric variables determined during the prepubertal (sexually immature) period and first and second estrous cycles in healthy female Beagle littermates to determine functional and anatomic changes of the lower urogenital tract during those periods.
Animals—5 female Beagle littermates.
Procedures—Urethral pressure profilometry, diuresis cystometry, and vaginourethrography were performed when dogs were 3.5, 4.5, 5, 6, 7, 8, 8.5, and 9 months old and during proestrus; estrus; early, middle, and late diestrus; and early and late anestrus of the first and second estrous cycles.
Results—At the end of the prepubertal period, values of urodynamic and morphometric variables increased significantly, compared with values at earlier times. Maximum bladder capacity developed when dogs were 9 months old. In all dogs, the bladder was intermittently located in an intrapelvic position during the prepubertal period; the bladder was intra-abdominal from the time dogs were 9 months old until the end of the study. Urethral pressure decreased significantly during estrus and early diestrus of the first and second estrous cycles. Bladder capacity increased significantly during diestrus of both estrous cycles. Urethral and vaginal lengths were significantly longer during proestrus and estrus than they were during anestrus.
Conclusions and Clinical Relevance—Values of lower urogenital tract urodynamic and morphometric variables were influenced by age and phases of the estrous cycle of immature and young adult Beagles in this study. Age of dog and phase of estrous cycle should be considered when interpreting urodynamic and vaginourethrography data.
Objective—To compare the urodynamic and hemodynamic effects of different dosages of phenylpropanolamine and ephedrine and determine effective dosages in increasing urethral resistance in female dogs.
Animals—20 sexually intact female Beagles.
Procedure—Dogs were allocated into 4 groups and received phenylpropanolamine once, twice, or 3 times daily, or ephedrine twice daily, for 14 days. On days 0, 7, and 14, urethral pressure profiles were performed while dogs were anesthetized with propofol. Variables recorded included maximum urethral pressure, maximum urethral closure pressure, integrated pressure, functional profile length, anatomic profile length, plateau distance, distance before maximum urethral pressure, and maximum meatus pressure. Arterial and central venous pressures were measured before anesthetic induction and 10 and 35 minutes after induction.
Results—Administration of phenylpropanolamine once daily or ephedrine twice daily significantly increased maximum urethral pressure and maximum urethral closure pressure. Values for integrated pressure were significantly increased after 14 days of once-daily administration of phenylpropanolamine. Variables did not change significantly from day 7 to day 14. Diastolic and mean arterial blood pressures increased significantly during the treatment periods, and arterial pressure decreased during propofol infusion.
Conclusions and Clinical Relevance—Oral administration of phenylpropanolamine once daily or ephedrine twice daily increased urethral resistance in clinically normal dogs and may be recommended for management of urethral sphincter mechanism incompetence. Treatment efficacy may be assessed after 1 week. Dogs with concurrent cardiovascular disease should be monitored for blood pressure while receiving α-adrenergic agents because of the effects on diastolic and mean arterial pressure.
Objective—To compare the urodynamic and morphologic effects of the administration of estriol alone and in combination with phenylpropanolamine on the lower portion of the urogenital tract in female dogs.
Animals—3 sexually intact and 3 spayed female Beagles without urinary incontinence.
Procedure—Dogs received estriol (2 mg, PO) once daily for 7 days followed by estriol (2 mg, PO) and phenylpropanolamine (1.5 mg/kg, PO) once daily for 7 days. Urethral pressure profilometry, diuresis cystometry, and vaginourethrography were performed before treatment (day 0) and at days 7 and 14. The maximum urethral pressure (MUP) and closure pressure (MUCP), urethral functional and anatomic profile lengths, integrated pressure (IP), plateau, distance before MUP, maximum meatus pressure, threshold pressure, threshold volume, compliance, urethral length, and vaginal length and width were measured.
Results—Before treatment, no urodynamic differences were observed between the 2 groups; however, vaginal length and width were significantly shorter in spayed dogs. Compared with day 0 values, estriol treatment significantly increased MUP, MUCP, and IP values at day 7, but at day 14, this effect decreased despite phenylpropanolamine administration. No morphologic changes from baseline were detected after either treatment in any dog.
Conclusions and Clinical Relevance—Data suggest that estriol mainly acts on the urethral sphincter mechanism by increasing urethral resistance in sexually intact and spayed female dogs without urinary incontinence. Administration of estriol and phenylpropanolamine did not increase the urethral resistance more than estriol alone. The urodynamic effects of estriol in female dogs with urinary incontinence remain to be elucidated.